← Eichor
Study identifier: NCT07070700 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Condition: Intrahepatic Cholangiocarcinoma (Icc)  ·  Sponsor: Fudan University

PhasePhase 2
Planned participants56
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Peng Wang, MD  ·  86-21-64041990  ·  peng_wang@fudan.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Zhongshan Hospital, Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07070700